Cooper-Standard Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cooper-Standard Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Feb 16, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Feb 16, 2024 |
| FY2023 | Dec 31, 2021 | $0 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Feb 25, 2019 |
| FY2017 | Dec 31, 2015 | $0 | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $0 | Feb 17, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $327.52M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $302.92M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $290.78M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $129.79M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $87.23M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $147.55M | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $65.54M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $80.21M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $97.87M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $115.51M | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.17M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($78.75M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($201.99M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($215.38M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($322.84M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | ($267.61M) | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | ($67.38M) | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | ($4.88M) | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $145.21M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | ($5.42M) | Feb 26, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $69.82M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $46.03M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($105.00M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($209.09M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | ($268.69M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $155.99M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $110.32M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $266.17M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $247.10M | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.64M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $82.82M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $84.11M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $80.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $89.96M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $101.61M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $114.85M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $122.53M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $127.97M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $117.79M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.37M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $207.55M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $215.74M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $199.46M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $227.11M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $263.61M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $302.50M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $314.81M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $340.96M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $356.65M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.44M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $76.37M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $117.28M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($36.15M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($115.51M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | ($15.93M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $97.70M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $149.39M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $313.11M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $365.47M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.73B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.87B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.96B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.23B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.61B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $2.64B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $2.62B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.73B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.49B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.92B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.87B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.96B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.86B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.90B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.99B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.76B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.77B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.87B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.77B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.49M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($125.77M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($81.30M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $107.71M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $324.88M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $607.11M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $856.18M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $824.81M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $826.57M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $697.36M | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $140.44M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $140.81M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $142.02M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $142.28M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $142.25M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $142.19M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $143.68M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $171.85M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $167.44M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($474.73M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($470.56M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($391.82M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($189.83M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $25.55M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $350.27M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $619.45M | Feb 22, 2021 |
| FY2019 | Jan 1, 2019 | $566.61M | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $569.22M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $508.72M | Feb 26, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $170.04M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $154.80M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $186.88M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $248.01M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $438.44M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $359.54M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $264.98M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $515.95M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $480.09M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $483.37M | Feb 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (11) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (12) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | (18) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | (15) | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | (4) | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | 8 | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 26, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (11) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (12) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | (18) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | (15) | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | (4) | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | 8 | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 26, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17.64M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 17.33M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 17.20M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 17.11M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 16.99M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | 16.90M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 16.84M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | 17.55M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 17.91M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | 17.69M | Feb 21, 2018 |